AOD-9604 Slow Titration for Sensitivity: How to Escalate Doses Safely

AOD-9604 is a synthetic 16-amino-acid peptide, also known as HGH fragment 176-191, that corresponds to the C-terminal region of human growth hormone. The peptide lacks FDA approval for any therapeutic use in the United States and can only be obtained from state-licensed 503A or 503B compounding pharmacies as of 2026. Since AOD-9604 remains unapproved by the FDA, no official prescribing information exists with an established dosing schedule, and clinical trials have not yet defined an optimal titration approach for patients responding to this peptide. The guidance below outlines the cautious, incremental dosing strategy employed in compounding pharmacy and clinical settings, clarifies its distinction from evidence generated in formal clinical trials, and identifies surveillance milestones that a prescriber may apply when managing a specific patient. This framework does not replace personalized dosing guidance from the patient's treating clinician.

The useful question for a sensitive patient is not "what is the correct AOD-9604 dose" but "what is the slowest step size and longest observation window that still lets a prescriber tell the difference between a transient injection reaction and a reason to stop."

Direct answer and its boundary

AOD-9604 is a fragment of human growth hormone that, in rodent studies and in a small human trial, has been reported to promote fat breakdown without the IGF-1 elevation or glucose effects seen with full-length growth hormone. It is not FDA-approved, has no FDA-recognized dosing schedule, and the widely circulated compounding-practice ramp (roughly 100-150 mcg starting, stepped up every 5 to 10 days toward a 250-300 mcg target) reflects prescriber consensus and compounding pharmacy convention, not trial-derived dosing. Peptide-sensitive patients are managed by starting low, extending the interval between steps, and stopping the increase (not just slowing it) if a reaction repeats or worsens. Anyone considering this peptide should treat the specific numbers below as a starting framework for a conversation with a licensed prescriber, not as a self-directed dosing instruction.

What AOD-9604 is, and what it is not

AOD-9604 is not full-length human growth hormone, and it is not the same molecule as other compounded peptides sometimes stacked with it (BPC-157, thymosin beta-4, tesamorelin, ipamorelin). It is a fragment peptide designed around the region of the hGH molecule associated with lipolytic activity. Preclinical work, most often cited to a 2001 rodent study, reported fat-mass reduction with this fragment without the glucose and lean-mass effects of the intact hormone. A separate, smaller human safety and tolerability trial has been described in the compounding and peptide literature, reportedly without significant changes in glucose, HbA1c, or IGF-1 across dose groups. We were not able to independently verify the exact study populations, durations, and endpoint results cited in secondary sources for either study line, and a reader relying on precise trial numbers should ask the prescriber to produce the primary publication before treating those numbers as established fact.

What is established, what is plausible, and what is not established

Established: AOD-9604 is not FDA-approved for any indication. It is sourced through compounding pharmacies rather than as an approved drug product, and compounded sterile products carry documented quality-control variability that the FDA has addressed in general guidance (FDA bulk drug substances page).

Plausible but unproven at the population level: that AOD-9604 produces clinically meaningful fat loss in humans at compounded doses, and that it is metabolically neutral (no glucose or IGF-1 effect) across the doses commonly compounded. The preclinical and small human data cited in practice suggest this direction but do not establish it with the confidence of an FDA-reviewed trial program.

Not established: any specific optimal titration schedule, any specific incidence rate for injection-site reactions or headache with this peptide, and any claim that slow titration changes long-term efficacy rather than short-term tolerability. These numbers, where cited in prescriber materials, come from clinical experience rather than published trials, and should be described to patients as such.

Why titration is used for a peptide that does not raise IGF-1 or glucose

Full-length growth hormone requires cautious titration partly because of systemic hormonal effects, fluid retention, and glucose changes. AOD-9604 is generally described as not producing those systemic effects at the doses used in practice. The rationale for titration with this peptide is therefore narrower: it is almost entirely about local tolerability (injection-site reactions) and non-specific symptoms (headache, transient nausea) rather than about avoiding a hormonal overshoot. That is a simpler dose-adjustment problem than titrating hGH, but "simpler" does not mean "unnecessary." A stepped approach still lets a prescriber isolate the dose at which a reaction appears, which is useful information whether or not a systemic hormonal risk is in play.

Titration pattern used in compounding practice

The pattern below describes common compounding-pharmacy and prescriber practice for peptide-sensitive patients. It is not a validated clinical protocol, and no randomized trial has tested this exact schedule against a faster ramp or a fixed dose. Any specific starting dose, step size, and target dose should be set by the prescriber based on the individual patient, concurrent medications, and body weight, not read off this page.

Typical starting point: a low once-daily subcutaneous dose, often in the 100-150 mcg range, given in the morning, with injection sites rotated between the left and right periumbilical area.

Typical step pattern: an increase every 5 to 10 days if the prior dose was tolerated, with sensitive patients using the longer end of that interval. A common target maintenance range cited in practice is 250-300 mcg once daily, reached over roughly two to four weeks, though some prescribers cap the dose at the lower end of that range for smaller patients.

Above the commonly cited target range: practice sources describe no established additional lipolytic benefit above roughly 300 mcg daily, and increasing risk-benefit uncertainty at higher doses that have not been characterized in available human data.

Clinician conversation and monitoring framework

This is a discussion and monitoring tool for a prescriber and patient to use together. It is not a self-titration script, and it does not replace clinical judgment about an individual patient's history, concurrent medications, or contraindications.

Escalation and stop decisions in the middle two columns are matters of individualized clinical judgment, not fixed rules. The table is a structure for the conversation, not a replacement for it. Any rechallenge after stopping for a side effect should be planned with the prescriber, typically starting well below the dose that triggered the reaction, and documented rather than repeated informally.

Special populations that change the plan

Patients on glucose-affecting medications (metformin, SGLT2 inhibitors, GLP-1 agonists): available human data on AOD-9604 has not shown a glucose effect, but adding a new subcutaneous peptide alongside a GLP-1 agonist can compound nausea. Separating injections by several hours and extending the step interval are reasonable, prescriber-directed adjustments; specific timing should be individualized.

Patients with a history of reactions to other compounded peptides: a slower interval and, in some practices, a small test dose before starting the standard ramp is described as an option, though this is off standard protocol and should be discussed and documented with the prescriber rather than self-initiated.

Older adults: lower lean mass and reduced renal clearance are reasons some prescribers start lower and extend intervals for older patients on any subcutaneous peptide, consistent with general dose-conservatism principles used for growth-hormone-related therapies in adults, even though AOD-9604's mechanism differs from full-length growth hormone.

Side effects reported in practice

Injection-site redness, mild tenderness, and localized swelling are the most commonly reported effects. Headache and transient nausea are also reported, particularly in the first week of a new dose. Precise incidence figures for these effects with AOD-9604 specifically have not been verified against a published trial for this article and should be treated as clinical impression rather than established rates. Rotating injection sites, using correct subcutaneous technique, and adequate hydration are reasonable general measures; they are not proven to change the underlying incidence of reactions to this specific peptide.

Comparison with full-length growth hormone for fat loss

Full-length growth hormone at fat-loss doses is associated in the literature with fluid retention, joint pain, and dose-dependent effects on insulin sensitivity, though exact incidence figures vary across studies and populations and should be confirmed against a specific trial or guideline before being quoted precisely. AOD-9604, by contrast, is designed around the portion of the hGH molecule not believed to drive IGF-1 elevation or glucose effects, and available human data has not shown those effects at the doses used in practice. The apparent trade-off is that AOD-9604's human fat-loss evidence is more limited and less consistently reported than the evidence base for full-length hGH in growth-hormone-deficient adults, a population that is not the same as the general body-composition patient using compounded AOD-9604. For patients who cannot tolerate hGH side effects or have a contraindication to growth hormone, such as active malignancy or uncontrolled diabetes, AOD-9604 is discussed in practice as an alternative with a narrower monitoring burden, not as an equivalent therapy.

Regulatory status and sourcing, dated 2026

AOD-9604 is not FDA-approved for any indication as of 2026. It is sourced through 503A patient-specific compounding pharmacies or 503B outsourcing facilities and appears on FDA's bulk drug substances list under evaluation for compounding use (FDA bulk drug substances page). Compounded sterile injectables carry documented variability in potency and sterility across facilities, which is a general concern FDA has raised about compounded sterile products. A specific failure rate for compounded sterile products is sometimes cited in secondary sources; we did not verify a specific percentage against a primary FDA survey for this article and recommend against repeating an unverified number. Patients should ask their compounding pharmacy for a certificate of analysis with third-party potency and sterility testing for each lot, and should never substitute "research-use-only" peptide sold online, which is not manufactured under pharmaceutical quality standards and is not intended for human injection.

When to seek care rather than continue titrating

Contact the prescriber promptly, and stop the peptide, for any of the following: signs of an allergic reaction (hives, facial or throat swelling, difficulty breathing), an injection-site reaction lasting more than a few hours or accompanied by fever, or any new symptom that seems disproportionate to a minor injection-site effect. Seek urgent or emergency care for breathing difficulty, throat swelling, chest pain, or fainting. These are general safety thresholds, not a complete list, and do not replace direct guidance from the prescribing clinician for a specific patient.